{
    "clinical_study": {
        "@rank": "148162", 
        "acronym": "APAF-CRT", 
        "arm_group": [
            {
                "arm_group_label": "Drug therapy", 
                "arm_group_type": "Experimental", 
                "description": "Control Arm: optimized drug therapy (plus implantable defibrillator (ICD) according to guidelines)"
            }, 
            {
                "arm_group_label": "Device:   AV junction ablation & CRT", 
                "arm_group_type": "Active Comparator", 
                "description": "AV junction ablation + CRT (CRT-P or CRT-D according to guidelines) + optimized drug therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "There is evidence of superiority of AV junction ablation strategy over pharmacological\n      therapy only for symptoms of atrial fibrillation, but not for heart failure,\n      hospitalization, morbidity and mortality. Hypothesis of trial is that AV junction ablation\n      is superior to pharmacological therapy as regard hospitalization and mortality"
        }, 
        "brief_title": "Atrioventricular Junction Ablation and Biventricular Pacing for Atrial Fibrillation and Heart Failure", 
        "completion_date": {
            "#text": "May 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Permanent Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Heart Failure"
            ]
        }, 
        "detailed_description": {
            "textblock": "Prospective randomized, controlled, investigator-initiated trial which consists of two\n      specific consecutive(overlapped) phases:\n\n      \"Morbidity trial\" (APAF-CRT morbidity). Small size (280 pts), follow-up 24 months. Primary\n      endpoint: combined of mortality due to heartfailure, hospitalization for heart failure or\n      atrial fibrillation or worsening heart failure. Predefined subgroup analysis for patients\n      with ejection fraction \u226435% versus >35%\n\n      \"Mortality trial\" (APAF-CRT mortality). Large size (pts included in morbidity trial plus\n      additional ~1500 pts, long-term follow-up (at least 4 years). Primary endpoint: total\n      mortality. Predefined subgroup analysis for patients with ejection fraction \u226435% versus >35%"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        To be eligible, each patient must be in the following condition:\n\n          1. Permanent atrial fibrillation (>6 months) which has been considered unsuitable for\n             ablation or failed ablation\n\n          2. Narrow QRS \u2264 110 ms\n\n          3. Severely symptomatic (atrial fibrillation-related symptoms), refractory to drug\n             therapy for rate control\n\n          4. At least one hospitalization related to atrial fibrillation and/or heart failure in\n             the previous  year (see definition below)\n\n        Exclusion Criteria:\n\n          1. New York Heart Association (NYHA) class IV and systolic blood pressure <80 mmHg\n             despite optimized therapy;\n\n          2. severe concomitant non-cardiac disease;\n\n          3. need for surgical intervention;\n\n          4. myocardial infarction within the previous 3 months;\n\n          5. previous implanted devices (PM/ICD/CRT)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1830", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137187", 
            "org_study_id": "CPMCV-01-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "Device:   AV junction ablation & CRT", 
                "description": "AV junction ablation", 
                "intervention_name": "AV junction ablation", 
                "intervention_type": "Procedure", 
                "other_name": "AV nodal ablation"
            }, 
            {
                "arm_group_label": "Device:   AV junction ablation & CRT", 
                "description": "Implantation of device for pacing and cardiac resynchronization therapy (CRT-P or CRT-D according to guidelines)", 
                "intervention_name": "CRT", 
                "intervention_type": "Device", 
                "other_name": "Cardiac resynchronization therapy"
            }, 
            {
                "arm_group_label": [
                    "Drug therapy", 
                    "Device:   AV junction ablation & CRT"
                ], 
                "description": "Optimized drug therapy for heart failure and atrial fibrillation rate control", 
                "intervention_name": "Optimized drug therapy", 
                "intervention_type": "Drug", 
                "other_name": "Pharmacological therapy"
            }, 
            {
                "arm_group_label": [
                    "Drug therapy", 
                    "Device:   AV junction ablation & CRT"
                ], 
                "description": "Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines", 
                "intervention_name": "ICD", 
                "intervention_type": "Device", 
                "other_name": "Implantable defibrillator"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Atrial fibrillation", 
            "Heart failure", 
            "Catheter ablation", 
            "Cardiac resynchronization therapy", 
            "Implantable defibrillator"
        ], 
        "lastchanged_date": "May 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lavagna", 
                    "country": "Italy", 
                    "zip": "16033"
                }, 
                "name": "Department of Cardiology, Ospedali del Tigullio"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Trial of Atrioventricular (AV) Junction Ablation and Biventricular Pacing Versus Optimal Pharmacological Therapy in Patients With Permanent Atrial Fibrillation", 
        "overall_contact": {
            "email": "mbrignole@asl4.liguria.it", 
            "last_name": "Michele Brignole, MD", 
            "phone": "+39 0185 329567"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "\"Morbidity trial\" end-points Primary end-point: a combined of (1) mortality due to heart failure, (2) hospitalization for heart failure or uncontrolled intolerable atrial fibrillation, or (3) worsening heart failure", 
                "measure": "Combined end-point", 
                "safety_issue": "No", 
                "time_frame": "Upto 3 years"
            }, 
            {
                "description": "\"Mortality trial\" end-points Primary end-point: total mortality", 
                "measure": "Total mortality", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "reference": {
            "PMID": "22187425", 
            "citation": "Chatterjee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, Choudhry NK, Singh JP. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. Circ Arrhythm Electrophysiol. 2012 Feb;5(1):68-76. doi: 10.1161/CIRCEP.111.967810. Epub 2011 Dec 20. Review."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137187"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "21606084", 
            "citation": "Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D, Luzi M, Tolosana JM, Navazio A, Menozzi C. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J. 2011 Oct;32(19):2420-9. doi: 10.1093/eurheartj/ehr162. Epub 2011 May 23."
        }, 
        "secondary_outcome": [
            {
                "description": "\"Morbidity trial\" end-points Secondary end-points: total mortality, total hospitalizations, hospitalization for heart failure and/or atrial fibrillation and worsening heart failure.", 
                "measure": "Major clinical events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "\"Mortality trial\" end-points Secondary end-point: cardiovascular mortality and hospitalization for heart failure or uncontrolled intolerable atrial fibrillation", 
                "measure": "Major clinical events", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "source": "Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}